Published in British journal of clinical pharmacology
Acetaminophen use and over-dosing increases in CFS, primarily due to increased use of OTC combinations treating upper respiratory cold/flu symptoms. Pharmacists should warn users to follow labeled dosing directions, especially during CFS.
Published in British journal of clinical pharmacology
Moderate hepatic impairment increased exposure to letermovir
Published in British journal of clinical pharmacology
To conclude, rhEGF, rhPDGF and autologous PRP significantly improved the healing rate when used as adjuvants to standard of care, of which rhEGF may perform better than other growth factors. The strength of most of the outcomes assessed was low and the findings may not be applicable for DFU with infection or osteomyelitis. The findings of this stud...
Published in British journal of clinical pharmacology
Adverse drug reactions were a significant cause of death in hospitalized patients, mainly haemorrhages and infections precipitated by drug-drug interactions. Risk factors for DRD were sex, age and number of drugs. Preventable DRD and measures to avoid them should be accurately assessed in further studies.
Published in British journal of clinical pharmacology
We conclude that the increased risk observed in the solely register-based study could partly be attributed to unmeasured confounding.
Published in British journal of clinical pharmacology
Psychotropic polypharmacy is common, despite limited evidence of risks and benefits. Increases in polypharmacy with multiple prescribers may be due to poor communication with patients and between health care professionals.
Published in British journal of clinical pharmacology
Clindamycin, doxycycline, quinolones, macrolides and phenoxymethylpenicillin in utero exposure were linked to organ-specific malformations. Amoxicillin, cephalosporins and nitrofurantoin were not associated with MCMs.
Published in British journal of clinical pharmacology
This study carried out in acutely hospitalized older people shows a high degree of inappropriate prescription among patients prescribed with antiplatelets for primary prevention, mainly due to overprescription. Further, a large proportion of patients who had had overt cardio- or cerebrovascular disease were underprescribed, in spite of the establis...
Published in British journal of clinical pharmacology
This is the first study to investigate the PopPK of exendin-(9-39) in humans. The final PopPK model was successfully used with preclinical toxicology findings to propose the optimal dosing regimen of exendin-(9-39) for clinical studies in neonates with HI, allowing for a more targeted dosing approach to achieve desired glycaemic response.
Published in British journal of clinical pharmacology
Drug management during different phases of AKD requires an individualised approach and frequent re-assessment. More research is needed to avoid drug associated harm and therapeutic failure.
